Antibody-based targeted conjugates for infectious diseases: Redefining targeted therapy beyond the oncology paradigm

A BSTRACT Infectious diseases remain a major global challenge due to pathogen evolution, antimicrobial resistance, and emerging threats. Conventional therapies are often limited by broad-spectrum toxicity and declining efficacy, underscoring the urgent need for precision strategies. Originally developed for oncology, antibody-based targeted conjugates (ABTCs) – including antibody-drug conjugates (ADCs) offer a promising platform that pairs monoclonal antibody specificity with diverse therapeutic payloads for targeted delivery. This narrative review was informed by a structured search of PubMed/MEDLINE, Web of Science, and Scopus from database inception through June 2026, with studies selected for their relevance to antibody- or Fc-based targeted payload delivery and classified as clinical, preclinical in vivo, in vitro proof-of-concept, or conceptual/emerging evidence. This review explores the emerging application of ABTCs as anti-infective agents, focusing on their potential to selectively target pathogens, eliminate infected host cells, or modulate host pathways critical for infection. Key design considerations, including antibody selection, linker chemistry, and payload diversification are discussed in the context of infectious disease biology. We further highlight current applications, including pathogen-targeted, infected cell-directed, and host-directed ABTCs approaches, as well as ADC-inspired antiviral strategies incorporating noncytotoxic and immunomodulatory payloads. Despite promising preclinical advances, significant barriers remain, including target identification, delivery limitations, safety concerns, and infection-specific pharmacokinetics. Overall, anti-infective ABTCs represent a conceptual shift toward precision therapeutics. Continued interdisciplinary innovation will be essential to translate this platform into clinically effective treatments for infectious diseases.

Authors

Institutions

Publication Details

Journal
Tzu Chi Medical Journal
Published
2026-11-13
DOI
https://doi.org/10.4103/tcmj.tcmj-d-26-00191
Primary Topic
Monoclonal and Polyclonal Antibodies Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Antibody-based targeted conjugates for infectious diseases: Redefining targeted therapy beyond the oncology paradigm

Shih‐Yen Lo, Chee-Hing Yang, Chia-Yu Wu, Shih-Han Ko et al.
2 links
Tzu Chi Medical Journal
Monoclonal and Polyclonal Antibodies Research
article

Antibody-based targeted conjugates for infectious diseases: Redefining targeted therapy beyond the oncology paradigm

Shih‐Yen Lo, Chee-Hing Yang, Chia-Yu Wu, Shih-Han Ko, Rong‐Hwa Jan, Ruei‐Min Lu
article en

Abstract

A BSTRACT Infectious diseases remain a major global challenge due to pathogen evolution, antimicrobial resistance, and emerging threats. Conventional therapies are often limited by broad-spectrum toxicity and declining efficacy, underscoring the urgent need for precision strategies. Originally developed for oncology, antibody-based targeted conjugates (ABTCs) – including antibody-drug conjugates (ADCs) offer a promising platform that pairs monoclonal antibody specificity with diverse therapeutic payloads for targeted delivery. This narrative review was informed by a structured search of PubMed/MEDLINE, Web of Science, and Scopus from database inception through June 2026, with studies selected for their relevance to antibody- or Fc-based targeted payload delivery and classified as clinical, preclinical in vivo, in vitro proof-of-concept, or conceptual/emerging evidence. This review explores the emerging application of ABTCs as anti-infective agents, focusing on their potential to selectively target pathogens, eliminate infected host cells, or modulate host pathways critical for infection. Key design considerations, including antibody selection, linker chemistry, and payload diversification are discussed in the context of infectious disease biology. We further highlight current applications, including pathogen-targeted, infected cell-directed, and host-directed ABTCs approaches, as well as ADC-inspired antiviral strategies incorporating noncytotoxic and immunomodulatory payloads. Despite promising preclinical advances, significant barriers remain, including target identification, delivery limitations, safety concerns, and infection-specific pharmacokinetics. Overall, anti-infective ABTCs represent a conceptual shift toward precision therapeutics. Continued interdisciplinary innovation will be essential to translate this platform into clinically effective treatments for infectious diseases.

Tzu Chi Medical Journal
Tzu Chi University (TW), Tzu Chi Foundation (TW), Hualien Tzu Chi Medical Center (TW), Academia Sinica (TW)
Good health and well-being
Monoclonal and Polyclonal Antibodies Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon